pegylated liposomal doxorubicin / Generic mfg. |
NCT00003334: Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract |
|
|
| Completed | 2 | | US | paclitaxel, pegylated liposomal doxorubicin hydrochloride | NYU Langone Health, National Cancer Institute (NCI) | Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma | 12/01 | | | |
NCT00189410: Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours |
|
|
| Completed | 2 | 140 | Europe | Pegylated Liposomal Doxorubicin and Carboplatin | AGO Study Group, MedServ. GmbH, Wiesbaden, Essex Pharma GmbH | Cancer of the Ovary Treated as 2nd Line Therapy, Muellerian Mixed Tumours, Tumours of the Uterus, Cervical Cancers, Non-Epithelial Ovarian Tumours | 09/05 | 09/06 | | |
NCT00097019: A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed |
|
|
| Completed | 2 | 53 | NA | bevacizumab | Genentech, Inc. | Ovarian Cancer | 05/06 | 05/06 | | |
NCT00312650: Doxil and Gemcitabine in Recurrent Ovarian Cancer |
|
|
| Terminated | 2 | 24 | US | liposomal doxorubicin and gemcitabine | Women and Infants Hospital of Rhode Island, Ortho Biotech, Inc. | Ovarian Carcinoma | 05/06 | 05/06 | | |
NCT00216645: Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy |
|
|
| Completed | 2 | 74 | Japan | doxorubicin hydrochloride | Janssen Pharmaceutical K.K. | Ovarian Neoplasms | | 11/06 | | |
NCT00780039: A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) |
|
|
| Completed | 2 | 58 | NA | Pegylated Liposomal Doxorubicin, SCH 200746, Carboplatin | Merck Sharp & Dohme LLC, Princess Margaret Hospital, Canada | Ovarian Neoplasms | 09/07 | 09/07 | | |
NCT00003896: S9912 Combination Chemo in Stage III Ovarian Cancer, |
|
|
| Completed | 2 | 68 | US | cisplatin, platinol, liposomal doxorubicin, pegylated liposomal doxorubicin hydrochloride, doxil, paclitaxel, taxol | Southwest Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 02/08 | 02/08 | | |
| Completed | 2 | 10 | Europe | recombinant interleukin-21, rIL-21, NN028, caelyx (pegylated liposomal doxorubicin) | Novo Nordisk A/S | Cancer, Ovarian Cancer | 01/09 | 01/09 | | |
NCT00653328: Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma |
|
|
| Terminated | 2 | 15 | US | atrasentan hydrochloride, ABT-627, Xinlay, doxil, pegylated liposomal doxorubicin hydrochloride (Doxil) | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI) | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 03/09 | 03/09 | | |
NCT00170573: Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer |
|
|
| Completed | 2 | 82 | Europe | Caelyx | North Eastern German Society of Gynaecological Oncology | Ovarian Cancer | 04/09 | 08/10 | | |
NCT00610792 / 2005-003962-40: Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens |
|
|
| Withdrawn | 2 | 91 | Europe | bortezomib, VELCADE, pegylated liposomal doxorubicin, CAELYX | Millennium Pharmaceuticals, Inc. | Ovarian Cancer | 09/09 | | | |
PRECEDENT, NCT00722592: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) |
|
|
| Completed | 2 | 162 | US | Vintafolide, EC145, pegylated liposomal doxorubicin (PLD), Doxil®, Caelyx®, EC20, 99mTc-EC20 | Endocyte | Ovarian Cancer | 09/10 | 12/12 | | |
|
|
|
|
|
|
|
|
|
|
NCT00698451: A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
|
|
| Completed | 2 | 54 | US | doxorubicin HCL liposome; bevacizumab; carboplatin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Centocor Ortho Biotech Services, L.L.C. | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 10/10 | 10/10 | | |
|
NCT00945139: Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) |
|
|
| Completed | 2 | 46 | US | Doxil, Doxorubicin, Avastin, Bevacizumab | New Mexico Cancer Care Alliance, Genentech, Inc., NYU Langone Health | Ovarian Cancer | 12/10 | 08/11 | | |
|
NCT00758732: Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma |
|
|
| Terminated | 2 | 34 | Europe | Docetaxel, Taxotere, Carboplatin, Liposomal doxorubicin, Caelyx | Hellenic Oncology Research Group, University Hospital of Crete | Ovarian Cancer | 03/11 | 03/11 | | |
| Completed | 2 | 33 | Europe | Pegylated liposomal doxorubicin, Caelyx, Panitumumab, Vectibix | Vejle Hospital | Epithelial Ovarian Cancer | 08/11 | 08/12 | | |
|
|
NCT00248248: DOXIL for Consolidation Therapy in Ovarian Cancer. |
|
|
| Completed | 2 | 45 | US | liposomal doxorubicin | Southeastern Gynecologic Oncology, Ortho Biotech, Inc. | Ovarian Neoplasm | 10/11 | 10/11 | | |
| Completed | 2 | 168 | US, Canada, Europe, RoW | ABT-888, ABT-888, veliparib, pegylated liposomal doxorubicin, doxil/caelyx, temozolomide, temozolomide, temodar/temodal | AbbVie (prior sponsor, Abbott) | Ovarian Cancer | 06/13 | 06/13 | | |
| Completed | 2 | 110 | Europe | Paclitaxel, Gemcitabine, Topotecan, Pegylated liposomal doxorubicin (PLD), BI 6727 | Boehringer Ingelheim | Ovarian Neoplasms | 06/14 | 06/14 | | |
NCT01991210 / 2012-005776-34: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) |
|
|
| Terminated | 2 | 95 | US, Canada, Europe | DNIB0600A, RO5541081, PLD | Genentech, Inc. | Ovarian Cancer | 08/16 | 08/16 | | |
|
| Completed | 2 | 119 | Europe | NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin | AGC Biologics S.p.A. | Ovarian Cancer | 12/16 | 12/16 | | |
NCT00032162: Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer |
|
|
| Completed | 1/2 | 63 | Europe | carboplatin, pegylated liposomal doxorubicin hydrochloride | AGO Study Group | Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma | 05/05 | | | |
NCT00052065: TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer |
|
|
| Completed | 1/2 | 28 | US | TLK286 | Telik | Ovarian Neoplasms | 03/06 | 03/06 | | |
NCT00237627: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 107 | US | PS-341, Doxil, pegylated liposomal doxorubicin, Velcade, Bortezomib | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 12/06 | 01/10 | | |
NCT00562185: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer |
|
|
| Withdrawn | 1/2 | 0 | US | carboplatin, doxorubicin hydrochloride | University of Texas Southwestern Medical Center, Ortho Biotech Clinical Affairs, L.L.C. | Ovarian Cancer | 03/09 | 03/09 | | |
NCT00903630: Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
|
|
| Terminated | 1/2 | 15 | US | Lenalidomide, Revlimid, liposomal doxorubicin, Caelyx® | Masonic Cancer Center, University of Minnesota, Celgene Corporation | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer | 08/11 | 08/11 | | |
NCT00182767: Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer |
|
|
| Completed | 1/2 | 45 | US | ixabepilone, BMS-247550, epothilone B lactam, Ixempra, pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox | National Cancer Institute (NCI) | Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer | 04/12 | 05/14 | | |
PITCH, NCT01637532: Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer |
|
|
| Completed | 1/2 | 21 | Europe | tocilizumab and interferon alpha 2-b, Carboplatin and Caelyx or doxorubicin | Leiden University Medical Center, University Medical Center Groningen | Recurrent Ovarian Cancer | 09/13 | 09/13 | | |